Brief: Panbela Initiates A Randomized, Double-Blind, Placebo-Controlled Study (Aspire)
26/01/2022 14:03
Jan 26 (Reuters) - Panbela Therapeutics Inc PBLA.O :
* PANBELA INITIATES A RANDOMIZED, DOUBLE-BLIND,
PLACEBO-CONTROLLED
STUDY (ASPIRE) OF NAB-PACLITAXEL AND GEMCITABINE WITH OR WITHOUT
SBP-101 IN SUBJECTS PREVIOUSLY UNTREATED FOR METASTATIC
PANCREATIC DUCTAL ADENOCARCINOMA
Source text for Eikon: ID:nGNX4bcRQG
Further company coverage: PBLA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Panbela Therapeutics
See all newsBrief: Panbela Therapeutics Announces Third Independent Safety Review Of Phase 3 Aspire Clinical Trial DSMB Recommended Continuation With No Trial Modification
Brief: Nasdaq Notifies Panbela Therapeutics Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard
Brief: Panbela Announces Pricing of Approximately $9 Mln Public Offering
U.S. STOCKS ON THE MOVE-Fisker, Best Buy, NuStar Energy
Brief: Panbela Therapeutics Announces Exercise Of Warrants And Issuance Of New Warrants